

DAFTAR PUSTAKA

1. Surachno RG, Bandiara R. Gangguan ginjal akut. Buku ajar ilmu penyakit dalam. VI ed. Jakarta;2014:854–59.
2. Roesli RM. Diagnosis dan pengelolaan gangguan ginjal akut. II ed. Jakarta; 2011:91–05.
3. Makris K, Spanon L. Acute kidney injury: Definition, pathophysiology, and clinical phenotypes. *Clin Biochem Rev.* 2016;37:140–52.
4. Agrawal M, Swartz R. Acute renal failure. *Am Fam Physician.* 2004;61:2077–88.
5. Abuelo JG. Normotensive ischemic renal failure. *New Eng J Med.* 2007;357:797–05.
6. Ahlstrom A, Tallgren M, Peltonen S, Rasanen P. Survival and quality life of patients requiring acute renal injury. *Intensive Care Med.* 2006;9:234–39.
7. Paweena S, Cruz DN, Gerd J, Abulfaray M. World insidence of aki : A Meta-analysis. *Clin J Am Sac Nephrol.* 2013;8:1482–93.
8. Roesli R. Kriteria Riffle: Cara yang mudah dan terpercaya untuk menegakkan diagnosis dini dan memprediksi prognosis aki. *Majalah ginjal dan hipertensi* 2002;166–72.
9. Ihsu CY, Ordonez JD, Chertow GM. The risk of acute renal failure in patients with chronic kidneys disease. *Kidney Int.* 2008;72:101–07.
10. Liano F, Junico E. The spectrum of acute renal failure in the intensive care unit compared with the seen in other settings. *Kidney Int.* 2004;53:516–24.
11. Lafrance JP, Miller DR. Aki associated with increased long-term mortality. *J Aw Soc Asphrol.* 2012;21:195 – 352.

12. Grams EG, Song Y, Ballew SH, Kimm H . A Meta-analysis of association of estimated ger, albuminum, age, race and sex with aki. AJKD. 2015;02:337–48.
13. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, *et al.* Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN. International Journal of Cancer. 2012;345–62.
14. Candrilli S, Bell T, Irish W. Acomparison of inpatient length of stay and cost among patients with hematology malignancy associated with and without aki. Clin Lymphoma Myeloma. 2008;08:44–51.
15. Pusat data dan informasi. Situasi penyakit kanker. Kementerian Kesehatan RI. 2015:24–29.
16. Kwok C. Management of side effects from chemotherapy. The Hongkong Anti Cancer Society. 2010:312–57.
17. Kelland L. The resurgence of platinum-based Chemotherapy. Nat Rev Cancer. 2007;213–56.
18. Chabner B. Barnett Rosenberg: In memoriam (1924–2009). Cancer Res. 2010;70:428–29.
19. Kociba RJ, Sleight SD. Acute toxicologic and pathologic effects of cisplatin in the male rats. Cancer Chemother Rep. 1971;21:813–38.
20. Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and update european journal of cancer. 2004;34:1522–34.
21. Ozkok A, Edelstein CL. Review article : Pathophysiology of cysplatin– induced acute kidney injury. Biomed research International. 2104;3:265–76.
22. National institute of health clinical trial database available from: <https://www.clinicaltrials.gov>. cited may 21, 2018.

23. Liu JQ, Cai GY, Wang SY, Song YH. The characteristic and risk factors for cisplatin-induced acute kidney injury in the elderly. Therapeutics and clinical risk management. 2018;67:213–56.
24. Dos Santos NA, Rodrigues C, Martins NM, Dos Santos AC. Cisplatin-induced nephrotoxicity and targets of nephroprotection :on update . Arch Toxicol. 2012;86(6):1233–50.
25. Lameire N. Nephrotoxicity of recent anti-cancer agents. Clin Kidney J. 2014;7:11–22.
26. Glezman IG, Jaimes EA. Chemotherapy and kidney injury. American Society of Nephrology. 2016;6:1–11.
27. Miller RP, Tagadavi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxin. 2010;2:33–46.
28. Oh GS, Kim HJ, Shen AH, Lee SB, Khadka D. Cisplatin-induced kidney dysfunction and perspective on improving treatment strategies. The Korean Society of Electrolyte Metabolism. 2014;21:34–46.
29. Schneider MP, Sullivan JC, Wach PF, Boesen EI, Yamamoto T. Protective role of extracellular superoxide dismutase in renal ischemia/reperfusion injury. Kidney Int. 2010;45:211–23.
30. Davis CA, Nick HS, Agarwal A. Manganese superoxide dismutase attenuates cisplatin-induced renal injury : Importance of superoxide. American Socitey of Nephrology. 2001;4;22–35.
31. Ighodaro OM, GgGANLOYE OA. First line defence antioxidants—sod, catalase , gpx; their fundamental role in the entire antioxidant defence grid. Alex J Med. 2017;21:34–46.
32. Bresciani G, Da cruz IBM, Gallego JG. Manganese superoxide dismutase and oxidative stress modulation. Advance in Clinical Chemistry. 2015;2;1–32.

33. McGinnes JE, Proctor PH, Demopoulos HB, Hokanson JA. Amelioration of cisplatin nephrotoxicity by superoxide dismutase. *Physiol Chem Phys*. 1979;213–40.
34. St Clair DK, Oberlet TD, Ho YS. Overproduction of human Mn—SOD modulates paraquat-mediated toxicity. *FEBS Lett*. 1991;23:111–39.
35. Eastgate J, Moreb J, Nick HS. A role for manganese SOD in radioprotection of hematopoietic stemcell. *Blood*. 1993;83:112–34.
36. Vaziri ND, Dicus M, Ho ND. Oxidative stress and dysregulation of SOD and NADPH oxidase in renal insufficiency. *Kidney International*. 2004;3:84–6.
37. Miller AF. Superoxide dismutase: ancient enzymes and new insights. *FEBS*. 2011;88:1889–97.
38. Ramesh G, Reeves WB. TNF alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. *The Journal of Clinical Investigation*. 2008;5:43–52.
39. Zhang B, Ramesh G, Norbury CC, Reeves WB. Cisplatin –induced nephrotoxicity is mediated by TNF alpha produced by renal proximal tubular cells. *International Society of Nephrology*. 2008;18:213–46.
40. Sedger LM, McDermott MF. TNF and TNF—receptors : from mediators of cell death and inflammation to therapeutic giant. *Cytokine and Growth Factor Reviews*. 2014;16:113–32.
41. Malyszko J, Kozlowska K, Kozlowski L. Nephrotoxicity of anticancer treatment. *Nephro Dial Transplant*. 2017;32:924–936.
42. Wang, D.; Lippard, S.J. Cellular processing of platinum anticancer drugs. *Nat. Rev. Drug Discov*. 2005;4:307–20.
43. Townsend DM, Tew KD, He L, King JB. Role of glutathione S—transferase pi in cisplatin—induced nephrotoxicity. *Biomed Pharmacother*. 2009;63:79–85.

44. Townsend DM, Deng M, Zhang L, Lapus M.G, Hanigan M.H. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. *J. Am. Soc. Nephrol.* 2003;26;32–43.
45. Bai J, Rodriguez AM, Melendez JA, Cederbaum AI. Overexpression of catalase in cytosolic or mitochondrial compartment protects HepG2 cells against oxidative injury. *J Biol Chem.* 2009;274;116–21.
46. Deng J, Kohda Y. Interleukin–10 inhibits ischemic and cisplatin–induced acute renal injury. *Kidney Int.* 2010;11:24–87.
47. Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, et al. Cisplatin–induced acute renal failure is associated with an increase in the cytokines interleukin (IL)–1 β , IL–18, IL–6, and neutrophil infiltration in the kidney. *J. Pharmacol Exp Ther.* 2007;28;87–99.
48. Oberley LW, Buether GR. Role of superoxide Dismutase in Cancer. *Cancer Research.* 1979;39;1141–49.
49. Oberley TD, Oberley LW. antioxidant enzyme levels in cancer. *Histol Histopathol.* 1997;12;525–35.
50. Khan MA, Tania M, Zhang DZ, Chen HC. Antioxidant enzyme and cancer. *Chin J Cancer Res.* 2010;22;87–92.
51. Zielinski CC, Budinsky AC, Wagner TM, Wolfran RM, Kostler WJ, Kubista M, et al. Defect of tnf alpha production and tnf alpha induced icam–1 expression in brca mutation cancer. *Breast Cancer Res Treat.* 2003;81;99–105
52. Li B, Vincent A, Cater J, Brantley DM, Polk DB, Yong PP. Low levels of tnf alpha increased tumor growth by inducing an endothelial phenotype pf monocyte recruited to tumor site. *Cancer Res.* 2009;69;338–50
53. Joseph SF, Ichim TE, Prnce SM, Kesari S, Marincola FM, Escobedo AR, et al. Unleashing endogenous tnf–alpha as a cancer immunotherapeutic. *J Transl Med.* 2018;16;242–50

54. Moon HH, Seo KW, Yoon KY, Shin YM, Lee SH. Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients. *World Journal of Gastroenterology*. 2014;30; 3510–3517.
55. Bunel V, Tournay Y, Nortier JL. Early detection of acute nephrotoxicity: interest of urinary monitoring of proximal tubular biomarkers. *Clin Kid J*.2017;10;639–647
56. Kidera Y, Kawakami H, Nakagawa K. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection.*Plos one*. 2014;9;319–30
57. Latcha S, Jaimes EA, Patil S, Glezman IG, Mehta S, Floumbaum CD. Long term renal outcomes after cisplatin treatment. *CJASN*.2016;11;1173–79
58. Nusseibeh E, Weber L, Won K, Reidt S. Chart review of predisposing factors to cisplatin-induced nephrotoxicity in patients with cancer. *JHOP*.2019;9;11–19
59. Chen WY, Hsiao CH, Chen YC, Ho CH, Hsing CH. Cisplatin nephrotoxicity might have a sex difference. An analysis based on women's sex hormone changes. *J cancer*.2017;8;3939–44
60. Nematbakhsh M, Ebrahimian S, Tooyserkani. Gender difference in cisplatin nephrotoxicity in a rat model greater intensity of damage in male than female. *Kidney international*.2013;83;1202–06
61. Nasri H. Cisplatin therapy and the problem of gender related nephrotoxicity. *NPJ*.2013;2;13–16
62. El-Arabey AA. Are testosterone and bcl6 critical players in cisplatin-induced nephrotoxicity in rats? . *J Nephrol Ther*.2018;8;315–319
63. Kong MJ, Kim JI, Park JW, Park KM. Gender difference in cisplatin-induced nephrotoxicity and the protective effect of starcation. *Redox biol*.2019;20;38–45

64. Espandiari P, Rosenzweig B, Zhang J, Zhou Y, Schnackenberg L, Vaidya VS et al. Age—related differences in susceptibility to cisplatin—induced renal toxicity. *J Appl Toxicol.* 2010;30:172—182
65. Prasetyanigrum M, Sari SP, Andalusia R. Evaluasi penurunan fungsi ginjal pasien yang mendapatkan cisplatin di rumah sakit kanker dharmais jakarta periode juli—desember 2012. *FFarmasi UI.* 2013
66. Prasaja Y, Sutandyo N, Andrajati R. Incidence of cisplatin—induced nephrotoxicity and associated factors among cancer patients in indonesia. *Asian pac j cancer prev.* 2015;16:1117—22
67. Gonzales R, Romay C, Borrego A, Hernandez F. Lipid peroxidase and antioxidant enzymes in cisplatin—induced chronic nephrotoxicity in rats. *Hindawi Pub Co.* 2005;3:139—145
68. Kuhad A, Pilkhuwal S, Sharma S, Tirkey N. Effect of curcumin on inflammation and oxidative stress in cisplatin—induced experimental nephrotoxicity. *J agri food chem.* 2007;55:10150—55
69. Bazmadegan G, AmirteimouryM, Kaedi A. Sumatriptan ameliorates renal injury induced by cisplatin in mice. *Iran J basic Med Sci.* 2019;22:563—567
70. Xiao MM, Gui LR, Li G, Qin Y, Li HD. NADPH oxidase 4 promotes cisplatin induced acute kidney injury via ros—mediated progammed cell death and inflammation. *Laboratory investigation.* 2017;00:1—16
71. Hassan SM, Khalaf MM, Sadek SA, Youssef A. Protective effects of apigenin and myricetin againts cispaltin—induced nephrotoxicity in mice. *Pharmaceutical Biology.* 2017;55:766—774
72. Mostafa ER, Saleh DO, Mansour DF. Cisplatin—induced of nephrotoxicity in rats: modulatory role of simvastatin and rosuvastatin againts apoptosis and inflammation. *Journal of applied pharmaceutical science.* 2018;8:043—050

73. Mapuskar KA, Wen H, Danniele G, Holanda, Rastogi P, Steinbach E et al. Persistent increased in mitochondrial superoxide mediates cispaltin-induced chronic kidney disease. Redox Biol. 2019;20:98–106

